A history of pioneering
Ferring was established 68 years ago in Sweden. Our Founder, Dr. Frederik Paulsen, became a pioneer in developing and selling pharmaceutical products based on natural peptide hormones produced by the body’s pituitary gland. He was convinced that these new compounds could play an invaluable role in the treatment of life-threatening conditions. Over six decades later, Dr. Paulsen’s conviction has been proven. Today, peptides remain core to many of our therapeutic treatments.
Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology.
Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. While Europe and the US are our largest markets, we are seeing our fastest growth in markets such as China and Japan.
At the heart of the business is a commitment to develop personalised treatments that work on the body’s own terms. In other words, we use peptides and proteins that work with the body’s own endocrine system to combat diseases and medical conditions.
We have our own manufacturing facilities in 11 countries, including several European countries as well as Argentina, Israel, India and China. We have also built new facilities in the USA. Including acquisitions to date, this means we have capabilities in both recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
‘Our job is to continue to
respond to the needs of today’s
patients as well as anticipate the
needs of tomorrow’s patients.’
A strategy focused on sustainable growth and leadership
As patient demographics for diseases and chronic conditions evolve, we must continue to respond to the needs of today’s patients as well as anticipate the needs of tomorrow’s patients.
One of the advantages of being a privately-owned business is that we can make our own decisions about how and when we invest, without being distracted by short-term quarterly results-driven performance.
A freshly-launched corporate mission statement will help us to focus on the next stage of growth. Our goal is to sustain growth at 50% higher than the industry average. Ferring will do this by harnessing its core competencies in science and business with other innovative technologies to create the next generation of solutions for patients and doctors. We plan to develop and deliver personalised healthcare solutions, integrating pharmaceutical products with diagnostics, data, devices, education and support services to optimise health outcomes.
Our intention is to be the world-leading, most trusted healthcare company in reproductive medicine and women’s health, and a leader in specialty areas within gastroenterology and urology. In order to do so, we need to invest more in research – specifically in new therapeutics, life cycle management and next generation healthcare solutions.
Power through research
Approximately 16% of our revenue goes back into research, which is in line with the industry average. With R&D facilities based in eight countries, our activities are focused on developing first-class therapeutic peptides and proteins in our key therapeutic areas. As disease demographics evolve, we are committed to creating new medicines and developing patient-friendly drug delivery systems – such as pen injections with easily adjustable digital dosage mechanisms.
We also work to adapt existing peptide based medications to meet specific medical needs. Often this means collaborating with scientific institutes and other biological and pharmaceutical companies throughout the world. Some of our key partners include the Salk Institute (US), Louis Pasteur Institute (France) the Karolinska Institute (Sweden) and the Chinese Academy of Science. We are also undertaking a large-scale research project with the March of Dimes (a US-based organisation) into the reasons for premature birth.
Our nine development sites include six product development laboratories in Copenhagen (Denmark), Parsippany (US), Glasgow (Scotland), Be’er Tuvia (Israel), Basel (Switzerland) and Mumbai (India). Our main pharmaceutical development hub is in Copenhagen. The Copenhagen and Parsippany sites drive and execute product innovation and development of new molecular entities as well as further development of our existing in-line products to better meet patient needs or address new disease areas.
Our core areas of therapeutic focus
Reproductive Medicine and Women’s Health
This is the most significant part of our business. We are already committed to therapies in fertility and obstetrics that harness the body’s natural processes to help couples conceive. We hope to offer new and innovative products in this area and provide treatments to aid every stage of the reproductive cycle. We also want to help improve women’s chances of surviving childbirth, and to overcome or manage diseases of the reproductive system.
We develop products to support and supplement our leading gastroenterology therapy for the treatment of Crohn’s disease and ulcerative colitis, as well as new treatment options for inflammatory bowel diseases and other lower gastro-intestinal conditions.
We are keen to build on our work in this area by introducing innovative products to supplement our existing portfolio of drugs.
In order to deliver on our ambition, our strategic priorities are focused on driving transformation initiatives designed to unleash efficiencies in the business, renewing our focus in R&D, accelerating a culture of innovation, and embedding stronger leadership principles in management.
‘This work, together with the CSR
culture we’re building, means
that if you’re a scientist, a college
graduate or a supplier, Ferring
should be the kind of company you
would want to work with.’